Abstract. Breast cancer is the most frequently diagnosed malignancy in women. However, the molecular mechanisms underlying breast cancer pathogenesis are not fully understood. The present study examined the role of miR-433 in breast cancer and investigated its underlying molecular mechanisms of action. Reverse transcription-quantitative polymerase chain reaction and western blot analysis were performed to analyze the level of microRNA (miRNA/miR)/mRNA and protein expression, respectively. Additionally, MTT assay was used to determined cell proliferation and viability. Cell apoptosis was measured by flow cytometry. A dual-luciferase reporter assay was used to confirm the identity of the downstream target of miR-433. The results revealed that miR-433 was downregulated in breast cancer tissues and cell lines. Overexpression of miR-433 inhibited cell proliferation and cell viability in BT-549 cells, whereas downregulation of miR-433 increased cell proliferation and cell viability in MDA-MB-231 cells. Further flow cytometry analysis revealed that miR-433 was able to induce apoptosis and also alter the levels of proteins expression of B-cell lymphoma-2 and Bcl-associated X. Bioinformatics analysis showed that RAC-γ serine/threonine-protein kinase (AKT3) was one of the downstream targets of miR-433, and luciferase reporter assay further confirmed that AKT3 is a direct target of miR-433. The knockdown of AKT3 was able to inhibit proliferation and viability in BT-549 cells. Overexpression of AKT3 prevented the inhibitory effects of miR-433 on proliferation and viability in BT-549 cells. The level of AKT3 mRNA expression was upregulated in breast cancer tissues compared with normal tissues and was inversely correlated with miR-433 expression levels. In summary, the results of the present study results indicate that the tumor-suppressive role of miR-433 may be mediated by regulating AKT3. miR-433 may therefore serve as a potential therapeutic target for breast cancer.
Introduction
Breast cancer is the most frequently diagnosed malignancy in women worldwide and poses a serious threat to women's health (1) . Breast cancer is the second-leading cause of cancer-associated mortality in 2015, accounting for ~11% of the total cancer mortalities in women (2, 3) . Although substantial progress has been made in surgical management and chemotherapy treatment, the rate of relapse in patients with advanced breast cancer remains high (4) (5) (6) . It is therefore essential to investigate further the molecular mechanisms underlying breast cancer development.
Previous findings concerning microRNAs (miRNAs/miRs) have substantially broadened knowledge concerning cancer pathogenesis (7, 8) . MiRNAs are a class of short non-coding RNA of ~20-22 nucleotides that can bind to complementary sequences in the 3' untranslated region (3'UTR) of mRNA to regulate gene expression. Therefore, miRNAs are involved in a number of cellular processes, including proliferation, apoptosis, development and differentiation (9) . Numerous studies have demonstrated that miRNAs can perform oncogenic or tumor suppressive roles in various types of cancers. Previous studies have demonstrated the functional roles of miR-433 in several types of cancer, including retinoblastoma (10), ovarian cancer (11) , bladder cancer (11) , oral squamous cell carcinoma (OSCC) (12) , gastric cancer (13) , hepatocellular carcinoma (HCC) (14) and lung cancer (15) . The downstream targets of miR-433 have been revealed to be strongly associated with cancer development, including Notch1, cAMP responsive element binding protein 1 (CREB1), paired box protein Pax-6 (PAX6), histone deacetylase 6 (HDAC6), kirsten rat sarcoma viral oncogene homolog and hepatocyte growth factor receptor (c-Met) (10, 12, 13, 16 4 and CHANGSHENG YE to be downregulated in these cancer types, and miR-433 was demonstrated to function as a tumor suppressor by inhibiting cell proliferation, migration and differentiation (10, (12) (13) (14) 16) . However, to the best of our knowledge, the role of miR-433 in breast cancer development is largely unknown. In the present study, miR-433 was downregulated in breast cancer tissues and breast cancer cell lines. In vitro functional assay indicated that miR-433 was able to inhibit cell proliferation, reduce cell viability and also decrease apoptosis in breast cancer cell lines. It was revealed that RAC-γ serine/threonine-protein kinase (AKT3) is a direct target of miR-433 in breast cancer cell lines. More importantly, analysis of clinical specimens further indicated that the level of miR-433 expression was inversely correlated with AKT3 expression in breast cancer tissues.
Materials and methods
Human clinical samples. Paired breast cancer and adjacent normal breast cancer tissues (~5 cm away from cancerous tissues) were obtained from 42 patients (mean age, 53 years old, age range: 27-68 years old) undergoing surgery in Nanfang Hospital (Guangzhou, China). The clinical samples were collected between July 2012 and December 2015. Informed consent was obtained from all patients enrolled in the present study, and all clinical studies were approved by the Ethics Committee of Nanfang Hospital. All the collected samples were snap-frozen for further reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis.
Cell lines and cell culture. The human breast epithelial MCF-10A cell line, and breast cancer cell lines BT-549, MCF-7, MDA-MB-453 and MDA-MB-231 were purchased from the Shanghai Institute of Cell Biology (Shanghai, China). All cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Inc.) under a humidified atmosphere of 5% CO 2 at 37˚C.
RNA isolation and RT-qPCR. miRNA and mRNA were extracted from clinical samples and cell lines using TRIzol reagent (Takara Biotechnology Co., Ltd., Dalian, China), according to the manufacturer's protocol. MiRNAs were reverse transcribed into cDNA using the One Step PrimeScript miRNA cDNA Synthesis kit (Takara Biotechnology Co., Ltd., Dailan, China), and mRNA was reverse transcribed into cDNA using the PrimeScript RT Reagent kit (Takara Biotechnology Co., Ltd.). RT-qPCR was performed by using the SYBR Green PCR kit (Takara Biotechnology Co., Ltd.) and the ABI 7500 FAST Real-Time PCR system (Applied Biosystems, Thermo Fisher Scientific, Inc.). The sequences of the primers used are as follows: miR-433 forward, 5'-TGC GGT ACG GTG AGC TGT C-3' and reverse, 5'-CCA GTG CAG GGT CCG AGG T-3'; AKT3 forward, 5'-ATG AGC GAT GTT ACC ATT GT-3' and reverse, 5'-CAG TCT GTC TGC TAC AGC CTG GAT A-3'; U6 forward: 5'-CGC TTC GGC AGC ACA TAT AC-3', reverse: 5'-TTC ACG AAT TTG CGT GTC AT-3'; GAPDH forward, 5'-GGT GAA GGT CGG AGT CAA CG-3', and reverse: 5'-CAA AGT TGT CAT GGA TGH ACC-3'. The qPCR thermocycling conditions used were 95˚C for 30 sec; 40 cycles of 95˚C for 5 sec and 60˚C for 30 sec; 95˚C for 15 sec, 60˚C for 60 sec and 95˚C for 15 sec. The relative expression level of miR-433 and AKT3 mRNA were calculated using 2 -∆∆Cq method (17) following normalization to U6 and GAPDH, respectively. All the experiments were performed in triplicates.
Reagents and transfection. The miR-433 mimics, and miR-433 inhibitors (anti-miR-433), as well as respective controls (miR-Ctrl and anti-miR-Ctrl), and the small interfering RNA (siRNA) targeting AKT3 (siAKT3), as well as its negative control (siNC), were obtained from Shanghai GeneChem, Inc. (Shanghai, China). The pGCL and pGCL-AKT3 plasmids were purchased from Shanghai GeneChem Co., Ltd. (Shanghai, China). In vitro transfection of these oligonucleotides (50 nM) was performed using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) in accordance with the manufacturer's instructions. At 48 h post-transfection, cells were processed for further experimentation.
Cell proliferation assay. Breast cancer cells (BT-549 and MDA-MB-231) were plated in 96-well plates overnight, and the cells were transfected with 50 nM miR-433 mimics, or anti-miR-433, or their respective controls (miR-Ctrl, anti-miR-Ctrl) using Lipofectamine 2000 reagent. At 48 h post-transfection, cells were further cultured in DMEM supplemented with 10% FBS for 0, 24, 48 or 72 h prior to the addition of MTT to each well. Following incubation with MTT for 4 h at 37˚C, MTT solution was removed, and dimethyl sulfoxide (DMSO) was added to each well. Absorbance was then measured at 490 nm using a spectrophotometer. For the AKT3 siRNA study and rescue experiments, the cells were transfected with siAKT3 or the negative control (siNC), miR-Ctrl with pGCL, miR-433 mimics + pGCL or miR-433 mimcis + pGCL-AKT3. A total of 48 h after transfection, the cells were further cultured for 48 h at 37˚C and the MTT assay was performed as aforementioned.
Cell viability assay. Breast cancer cells (BT-549 and MDA-MB-231) were plated in 96-well plates overnight, and the cells were transfected with miR-433 mimics, anti-miR-433, miR-Ctrl or anti-miR-Ctrl. A total of 48 h after transfection, the cells were further cultured in serum-free DMEM for 0, 24, 48 or 72 h prior to the addition of MTT to each well. Following incubation with MTT for 4 h at 37˚C, the MTT solution was removed and DMSO was added to each well followed by measuring the absorbance at 490 nm using a spectrophotometer. For the AKT3 siRNA study and rescue experiment, the cells were transfected with siAKT3 or the negative control (siNC), miR-Ctrl + pGCL, miR-433 mimics + pGCL, or miR-433 mimcis + pGCL-AKT3, and 48 h after transfection, the cells were further cultured for 48 h at 37˚C before MTT assay was conducted as aforementioned.
Luciferase reporter assay. The predicted targets of miR-433 were analyzed by using TargetScan (version 7.1), and AKT3 was found to one of the targets of miR-433. The entire human AKT3 3'UTR, harboring the miR-433 target sequence as well as the mutated (MUT) seed sequence, were purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, China). The AKT3 3'UTR reporter was generated by inserting the entire wild-type (WT) 3'UTR or MUT 3'UTR of AKT3 mRNA into psiCHECK-2 vector (Promega Corporation, Madison, WI, USA). For the luciferase reporter assay, the cells (BT-549 and MDA-MB-231) were co-transfected with the AKT3 3'UTR reporter and the miR-433 mimics, anti-miR-433 or their respective controls (miR-Ctrl, anti-miR-Ctrl) using the Lipofectamine 2000 reagent, and 48 h following transfection, firefly and Renilla luciferase activities were measured by using the Dual Luciferase Assay kit (Promega Corporation, Madison, WI, USA).
Cell apoptosis analysis. Breast cancer cells (BT-549 and MDA-MB-231) were plated in 6-well plates overnight, and the cells were then transfected with miR-433 mimics, anti-miR-433 or respective controls (miR-Ctrl and anti-miR-Ctrl). At 48 h after transfection, the cells were harvested and processed, and double staining with annexin V-fluorescein isothiocyanate (FITC) and propidium iodide was performed using the Annexin V-FITC Apoptosis Detection kit (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer's protocol. Cell apoptosis was analyzed with a FACScan flow cytometer (BD Biosciences), and the cell apoptotic rates were analyzed by the BD CellQuest Pro™ Software (Version 5.1; BD Biosciences).
Western blot analysis. Proteins from breast cancer cells were extracted using a modified Radioimmunoprecipitation Assay buffer (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) with proteinase inhibitor cocktail (Complete mini; Roche Applied Science, Penzberg, Germany). The concentration of protein was measured using the BCA kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA) Protein lysates (30 µg) were separated on 10 % SDS-PAGE and transferred to polyvinylidene difluoride membranes. The membranes were blocked with 5% skimmed milk for 1 h at room temperature, followed by incubating with the following primary antibodies: Rabbit polyclonal anti-B-cell lymphoma 2 (Bcl-2) antibody (1:1,500; cat. no. ab59348; Abcam, Cambridge, USA), rabbit polyclonal anti-Bcl-associated X (Bax) antibody (1:1,000; cat. no. ab53154; Abcam), rabbit polyclonal anti-AKT3 antibody (1:1,000, cat. no. ab189643; Abcam) and rabbit polyclonal anti-GAPDH antibody (1:2,000, cat. no. ab9485; Abcam) overnight at 4˚C. The membranes were subsequently incubated with horseradish peroxidase conjugated secondary antibody (1:2,000, cat. no. ab205718; Abcam) and visualized with enhanced chemiluminescence reagent (GE Healthcare Life Sciences, Little Chalfont, UK) according to the manufacturer's protocol.
Statistical analysis. All data are presented as the mean ± standard deviation, and data analysis was performed using GraphPad Prism (version 6.0; GraphPad Software, Inc., La Jolla, CA, USA). Significant differences between groups for clinical samples were analyzed by paired t-test. For in vitro functional assay, significant differences were analyzed by one-way analysis of variance followed by Dunnett's multiple comparison test or unpaired t-test. The correlation between miR-433 levels and AKT3 mRNA levels in breast cancer tissues was analyzed by Spearman's correlation test. P<0.05 was considered to indicate a statistically significant difference.
Results

miR-433 expression is downregulated in breast cancer tissues and breast cancer cell lines.
To assess the role of miR-433 in breast cancer, the levels of miR-433 expression in 42 paired breast cancer and normal adjacent breast tissues were examined by RT-qPCR. The results revealed that the level of miR-433 expression was significantly lower in cancer tissues compared with normal adjacent breast tissues (Fig. 1A) . In addition, the relative expression levels of miR-433 in different breast cancer cells lines were also determined. It was indicated that the levels of miR-433 expression in the breast cancer cell lines BT-549, MCF-7, MDA-MB-453 and MDA-MB-231 was downregulated when compared with the expression level of miR-433 in normal breast cell line, MCF-10A (Fig. 1B) . These data indicate that miR-433 may be a tumor suppressor in breast cancer. 
miR-433 inhibits proliferation in breast cancer cell lines.
To gain insights into the underlying mechanisms of action of miR-433 in breast cancer, in vitro functional assays including MTT and cell viability assays were performed. RT-qPCR results revealed that the expression level of miR-433 was increased >10 fold in BT-549 cells transfected with miR-433 mimics, while the expression level of miR-433 was significantly decreased in MDA-MB-231 cells transfected with anti-miR-433 ( Fig. 2A) . The MTT assay revealed that BT-549 cells transfected with miR-433 mimics exhibited lower proliferative activity when compared with cells transfected with miR-Ctrl. Additionally, the downregulation of miR-433 in MDA-MB-231 cells by transfection with anti-miR-433 was able to increase cell proliferation (Fig. 2B) . The viability of BT-549 cells transfected with miR-Ctrl or miR-433 mimics and MDA-MB-231 cells transfected with anti-miR-Ctrl or anti-miR-433 was also examined. As shown in Fig. 2C , transfection with miR-433 mimic in BT-549 cells reduced cell viability when compared with miR-Ctrl transfection, whereas MDA-MB-231 cells transfected with anti-miR-433 exhibited a higher cell viability when compared with cells transfected with anti-miR-Ctrl (Fig. 2C) . These results indicate that miR-433 exerts a tumor suppressive function in breast cancer cells.
miR-433 induces apoptosis in breast cancer cell lines.
To examine the role of miR-433 on cell apoptosis, flow cytometry and western blotting experiments were performed. Flow cytometry results demonstrated that transfection of BT-549 cells with the miR-433 mimic significantly increased the proportion of apoptotic cells when compared with cells transfected with miR-Ctrl, whereas the proportion of apoptotic MDA-MB-231 cells transfected with anti-miR-433 was significantly lower compared with cells transfected with anti-miR-Ctrl (Fig. 2D) . Expression levels of the apoptosis-associated proteins, including Bcl-2 and Bax, were examined. Overexpression of miR-433 in BT-549 cells decreased the level of Bcl-2 protein expression and increased the level of Bax protein expression, whereas downregulation of miR-433 in MDA-MB-231 cells upregulated Bcl-2 expression and downregulated Bax expression (Fig. 2E ).
AKT3 is a direct target of miR-433.
To predict the downstream targets of miR-433, the predicted targets were analyzed by using TargetScan (version 7.1). Of the predicted targets, AKT3 was selected for further experiments owing to its known role in cancer development (18) . To confirm that AKT3 was a target of miR-433, AKT3 3'UTR luciferase reporter plasmids containing WT or MUT potential binding sites for miR-433 were constructed and a dual-luciferase reporter assay was conducted (Fig. 3A) . The results of this assay revealed that overexpression of miR-433 significantly decreased luciferase activity in BT-549 cells transfected with plasmids containing (Fig. 3B) . Downregulation of miR-433 by anti-miR-433 transfection significantly increased luciferase activity in MDA-MB-231 cells transfected with plasmids containing the WT 3'UTR of AKT3, but not in cells transfected with plasmids containing the MUT 3'UTR of AKT3 (Fig. 3B) . In addition, BT-549 cells transfected with miR-433 mimics expressed lower levels of ATK3 mRNA compared with cells transfected with miR-Ctrl (Fig. 3C) , and MDA-MB-231 cells transfected with anti-miR-433 exhibited increased AKT3 mRNA the expression levels of AKT3 mRNA when compared to with cells transfected with anti-miR-Ctrl (Fig. 3C) . These results suggest that AKT3 may be a direct target of miR-433.
Inverse correlation between the expression levels of miR-433 and AKT3. To further examine the role of AKT3 in breast cancer cells, a siRNA experiment to determine the effect of AKT3-knockdown on proliferation and cell viability of breast cancer cells was performed. As shown in Fig. 4A and B, AKT3-knockdown in BT-549 cells by transfection with siAKT3 significantly decreased the mRNA and protein expression levels ( Fig. 4A and B) . Knockdown of AKT3 in BT-549 cells was able to decrease cell proliferation and viability ( Fig. 4C and D) . To further confirm that ATK3 is a downstream target of miR-433, a rescue experiment was also performed by transfecting BT-549 cells with miR-433 mimics and AKT3-expressing vectors. The results revealed that overexpression of AKT3 in miR-433-transfected BT-549 cells significantly prevented the inhibitory effect of miR-433 on cell proliferation and cell viability (Fig. 4E and F) . Analysis of clinical samples revealed that the level of AKT3 mRNA expression in breast cancer tissues was significantly higher compared with adjacent normal breast cancer tissues (Fig. 4G) , and Spearman's correlation analysis demonstrated that miR-433 expression level was inversely correlated with the level of AKT3 mRNA expression (Fig. 4H) .
Discussion
Recently, substantial effort has been made to improve diagnostic techniques and therapeutic approach for breast cancer. However, the limited efficacy of novel therapeutics has become a major obstacle owing to the inadequate understanding of molecular mechanisms underlying breast cancer pathogenesis (4) (5) (6) . The present study demonstrated the tumor suppressive role of miR-433 in breast cancer cells. miR-433 expression was found to be downregulated in breast cancer tissues and breast cancer cell lines, and miR-433 overexpression was revealed to inhibit cell proliferation and viability. Additionally, overexpression of miR-433 was able to induce apoptosis possibly via targeting of AKT3 in breast cancer cells. Clinical sample analysis further confirmed that miR-433 and AKT3 expression levels were inversely correlated in breast cancer tissues.
The functional role of miR-433 has been determined in various types of cancer. miR-433 has been demonstrated to be downregulated in several types of cancer tissue, including (10, (12) (13) (14) 16) . Consistent with this, the results of the present study also demonstrated the downregulation of miR-433 in breast cancer tissues, which suggests that miR-433 may be tumor-suppressive in breast cancer tissues. To gain further understanding of miR-433 in breast cancer development, MTT assay was performed in the present study to assess cell viability and proliferation, and it was indicated that transfection with miR-433 was bale to inhibit cell proliferation and reduce the viability of breast cancer cells. These findings were in agreement with those of previous studies, as miR-433 was shown to negatively regulate cell proliferation, migration and invasion in retinoblastoma cells (10) . Exogenous expression of miR-433 was able to significantly inhibit cell proliferation, colony formation, migration and invasion in bladder cancer cells (16) . Restoring miR-433 expression in OSCC cells dramatically suppressed cell growth, invasion and migration, (12) and ectopic expression of miR-433 inhibited cell proliferation, cell cycle progression, cell migration and invasion in gastric cancer cells (19) . Collectively, these results indicate that miR-433 has a tumor-suppressive role in cancer cells in vitro. In addition, overexpression of miR-433 induced cell apoptosis and altered the expression levels of apoptosis mediators (Bcl-2 and Bax). miR-433 induced cell cycle arrest and cell apoptosis in retinoblastoma cells (10) , and miR-433 accelerated apoptosis in human dental pulp cells (20) . Therefore, the results of these previous studies indicate that the inhibitory effect of miR-433 on breast cancer cell proliferation and cell viability may involve the acceleration of cell apoptosis.
AKT is a key mediator of the phosphoinositide 3-kinase (PI3K) pathway, and was found to regulate breast cancer progression and metastasis by promoting migration and invasion (21, 22) . Activation of the PI3K/AKT signaling pathway is observed in >80% of breast cancer patients (23) . AKT3 is one of the three isoforms of AKT (AKT1, AKT2, and AKT3), and has been demonstrated to serve notable roles in breast cancer development (24) (25) (26) (27) (28) (29) . AKT3 amplification has been suggested to represent a potentially relevant oncogenic event in the subset of triple-negative breast cancer (TNBC) (29) . Downregulation of AKT3 inhibited the growth of TNBC cell lines in 3D spheroid cultures and in mouse xenograft models (24) , whereas upregulation of AKT3 conferred resistance to the AKT inhibitor MK2206 in breast cancer, and suppression of AKT3 by miR-489 increases chemosensitivity in breast cancer (28) .
In the present study, it was found that AKT3 is a direct target of miR-433, which was confirmed by luciferase reporter assay. The knockdown of AKT3 was also able to significantly inhibit proliferation and viability of breast cancer cells. The level of AKT3 expression was inversely correlated with miR-433 expression in breast cancer tissues. Collectively, these data indicate that miR-433 was able to inhibit cell proliferation and cell viability by modulating AKT3. However, caution must be exercised as miR-433 may have downstream targets other than AKT3. Previous studies have found that miR-433 targets Notch1, CREB1, PAX6, HDAC6, KRAS and c-Met in other types of cancer (10, 12, 13, 16) . Therefore, future studies must assess other targets of miR-433 in breast cancer.
In summary, in the present study, it was revealed that miR-433 was downregulated in breast cancer tissues and cell lines. To the best of our knowledge, the present study is the first to reveal that miR-433 may function as a tumor suppressor by targeting AKT3 in breast cancer cells. Therefore miR-433 may be a potential biomarker for breast cancer diagnosis and may serve as a novel target for breast cancer therapy. 
